Drug intelligence / Profile preview

HB-110 (Dong-A Pharmaceutical)

Development stage: Unknown
Lead developer: Genexine
Modality: DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Prophylactic Vaccines → Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

**HB-110** is an investigational therapeutic DNA vaccine for **chronic hepatitis B**. It is a co-formulated mixture of three naked plasmid DNA vectors encoding hepatitis B virus envelope proteins S and L, hepatitis B virus core protein and polymerase, and mutant human interleukin-12. Administered intramuscularly, including by electroporation in clinical studies, HB-110 is intended to restore or amplify HBV-specific cellular immune responses in people with chronic HBV infection. It was evaluated in completed Phase 1 studies with background nucleoside analogue therapy including adefovir and entecavir.

Targets

HBc (Hepatitis B virus core protein)HBV Pol (Hepatitis B virus polymerase)L-HBsAg (Hepatitis B virus large envelope protein)S-HBsAg (Small envelope protein)IL-12R (Interleukin-12 receptor)

Beyond the preview

Go deeper on HB-110 (Dong-A Pharmaceutical).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HB-110 (Dong-A Pharmaceutical).

Explore the full profile